Pliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $47.00 at JPMorgan Chase & Co.

Pliant Therapeutics (NASDAQ:PLRX – Get Rating) had its target price trimmed by JPMorgan Chase & Co. from $51.00 to $47.00 in a research report released on Friday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

PLRX has been the topic of a number of other reports. SVB Leerink increased their target price on shares of Pliant Therapeutics from $33.00 to $45.00 and gave the stock an outperform rating in a report on Tuesday, January 24th. Oppenheimer increased their target price on shares of Pliant Therapeutics from $43.00 to $44.00 and gave the stock an outperform rating in a report on Friday. Stifel Nicolaus began coverage on shares of Pliant Therapeutics in a report on Tuesday, December 13th. They set a buy rating and a $33.00 target price on the stock. Royal Bank of Canada reduced their target price on shares of Pliant Therapeutics from $60.00 to $58.00 and set an outperform rating on the stock in a report on Friday. Finally, Citigroup reduced their target price on shares of Pliant Therapeutics from $55.00 to $50.00 and set a buy rating on the stock in a report on Monday. Ten research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of Buy and an average target price of $46.70.

Pliant Therapeutics Stock Performance

Shares of PLRX stock opened at $28.20 on Friday. The firm’s 50 day moving average price is $28.86 and its 200-day moving average price is $23.68. The company has a debt-to-equity ratio of 0.03, a quick ratio of 14.23 and a current ratio of 14.23. Pliant Therapeutics has a one year low of $3.96 and a one year high of $36.64. The firm has a market cap of $1.66 billion, a P/E ratio of -9.49 and a beta of 1.44.

Insider Buying and Selling at Pliant Therapeutics

In related news, General Counsel Mike Ouimette sold 2,928 shares of the stock in a transaction on Thursday, December 22nd. The shares were sold at an average price of $19.38, for a total value of $56,744.64. Following the transaction, the general counsel now directly owns 5,947 shares of the company’s stock, valued at approximately $115,252.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, General Counsel Mike Ouimette sold 2,928 shares of the stock in a transaction on Thursday, December 22nd. The shares were sold at an average price of $19.38, for a total value of $56,744.64. Following the transaction, the general counsel now directly owns 5,947 shares of the company’s stock, valued at approximately $115,252.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bernard Coulie sold 15,000 shares of the stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $33.61, for a total transaction of $504,150.00. Following the completion of the transaction, the chief executive officer now directly owns 240,112 shares in the company, valued at $8,070,164.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 274,889 shares of company stock valued at $7,945,700. Insiders own 6.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PLRX. Acadian Asset Management LLC purchased a new position in shares of Pliant Therapeutics in the 1st quarter valued at $27,000. UBS Group AG boosted its stake in Pliant Therapeutics by 18.4% during the 2nd quarter. UBS Group AG now owns 3,537 shares of the company’s stock worth $28,000 after purchasing an additional 550 shares during the period. Salem Investment Counselors Inc. boosted its stake in Pliant Therapeutics by 14.5% during the 2nd quarter. Salem Investment Counselors Inc. now owns 7,735 shares of the company’s stock worth $62,000 after purchasing an additional 980 shares during the period. XTX Topco Ltd acquired a new stake in Pliant Therapeutics during the 1st quarter worth $89,000. Finally, Dimensional Fund Advisors LP acquired a new stake in Pliant Therapeutics during the 1st quarter worth $95,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Pliant Therapeutics Company Profile

(Get Rating)

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.